<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121187">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02125071</url>
  </required_header>
  <id_info>
    <org_study_id>I.V. Hepabig injection_IIT</org_study_id>
    <nct_id>NCT02125071</nct_id>
  </id_info>
  <brief_title>Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation</brief_title>
  <acronym>LT</acronym>
  <official_title>An Exploratory Clinical Trial to Evaluate the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V.
      Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>anti-HBs titer</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The anti-HBs titer is measured on the day of LT, day 1, week 1, week 4, week 12 and week 24, to determine the pharmacokinetic characteristic of Hepabig I.V. injection</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Hepabig</arm_group_label>
    <description>Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample Collection</intervention_name>
    <description>Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.</description>
    <arm_group_label>Hepabig</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Those who receiving I.V. Hepabig injection for prevention of hepatitis B relapse after
        liver transplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female â‰¤18 years old

          -  Patients who understand the informed consent form and signed the form voluntarily

          -  Patients who underwent liver transplantation due to HBV related disease and will be
             treated for prevention of hepatitis B relapse after liver transplantation

        Exclusion Criteria:

          -  Multi-organ recipient or reimplantation

          -  IgA Deficiency

          -  Serious nephropathy

          -  Serious cardiovascular system failure within 6 months

          -  Ischemic or hemolytic anemia

          -  Condition of immunosuppression and immunodeficiency

          -  Hypersensitivity or allergic to blood products

          -  HIV or HCV positive

          -  Participation to other clinical trial within 3 months

          -  Pregnancy or breast feeding

          -  Those who the investigator determines inappropriate to participate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Gu Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University, Seoul St Mary Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Gu Kim, MD, PhD</last_name>
    <phone>+82-2258-1158</phone>
    <email>kimdg@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seung Hoon Han, MD</last_name>
    <phone>+82-2-2258-7884</phone>
    <email>waystolove@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Catholic University, Seoul St Mary Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Gu Kim, MD, PhD</last_name>
      <phone>02-2128-1158</phone>
      <email>kimdg@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dong Gu Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>March 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Gu Kim</investigator_full_name>
    <investigator_title>MD, Phd</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
